BioCentury | Oct 27, 2020
Deals

SPACs & vax: a BioCentury podcast

...not SPAC specialists running the deals, but blue chip...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...new cohort of SPACs is backed by blue chip...
...now.“In the past few quarters we’ve seen blue chip...
...post-merger valuation with more confidence. And the blue chip...
BioCentury | Sep 25, 2020
Product Development

Flagship’s Valo takes stab at cloud-based R&D with $96.5M and longitudinal human data

...platform is geared to guide everything from target discovery to clinical trial design.Through Valo, the blue chip...
BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...is a massive information advantage.”The framework agreement has been a key driver for OSI’s fund-raising. Blue chip...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...launched in the past eight years with sizable series A rounds coming from syndicates of blue chip...
BioCentury | Sep 3, 2019
Financial News

Achilles adds £100M to move neoantigen T cell therapy into the clinic

...Achilles added blue chip investors in its series B round to finance the progression of its neoantigen...
BioCentury | Dec 9, 2017
Strategy

Genmab’s second act

...de Winkel said. “But the difference now is I’m not so willing to make my blue chip...
BioCentury | Aug 7, 2015
Financial News

Biotech stocks off on Thursday

Biotech indices dipped Thursday, as the BioCentury 100 lost 351.02 (4%) to 7562.21, while the NASDAQ Biotechnology Index shed 159.73 (4%) to 3887.75. The NASDAQ was off 83.50 (2%) to 5,056.44, while the Dow Jones...
BioCentury | Jul 9, 2015
Strategy

The priority of proximity

...to take advantage of the whole network of research in the Nordic region. "Within the blue chip...
Items per page:
1 - 10 of 89
BioCentury | Oct 27, 2020
Deals

SPACs & vax: a BioCentury podcast

...not SPAC specialists running the deals, but blue chip...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...new cohort of SPACs is backed by blue chip...
...now.“In the past few quarters we’ve seen blue chip...
...post-merger valuation with more confidence. And the blue chip...
BioCentury | Sep 25, 2020
Product Development

Flagship’s Valo takes stab at cloud-based R&D with $96.5M and longitudinal human data

...platform is geared to guide everything from target discovery to clinical trial design.Through Valo, the blue chip...
BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...is a massive information advantage.”The framework agreement has been a key driver for OSI’s fund-raising. Blue chip...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...launched in the past eight years with sizable series A rounds coming from syndicates of blue chip...
BioCentury | Sep 3, 2019
Financial News

Achilles adds £100M to move neoantigen T cell therapy into the clinic

...Achilles added blue chip investors in its series B round to finance the progression of its neoantigen...
BioCentury | Dec 9, 2017
Strategy

Genmab’s second act

...de Winkel said. “But the difference now is I’m not so willing to make my blue chip...
BioCentury | Aug 7, 2015
Financial News

Biotech stocks off on Thursday

Biotech indices dipped Thursday, as the BioCentury 100 lost 351.02 (4%) to 7562.21, while the NASDAQ Biotechnology Index shed 159.73 (4%) to 3887.75. The NASDAQ was off 83.50 (2%) to 5,056.44, while the Dow Jones...
BioCentury | Jul 9, 2015
Strategy

The priority of proximity

...to take advantage of the whole network of research in the Nordic region. "Within the blue chip...
Items per page:
1 - 10 of 89